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 Breast cancer is a formidable disease despite all the 
advances in health technology. Portuguese women have a 
cumulative risk of breast cancer of 7.43%, a cumulative risk 
of dying of breast cancer of 1.32%,1 and this illness tragi-
cally affects not only women with the disease as well as 
those around them. While breast cancer screening is an at-
tractive idea, it is also very controversial. In this paper, we 
argue that the recommendation “choose not to postpone 
breast cancer screening to age 50; choose to start breast 
cancer screening annually at age 40” is a poor candidate for 
a strong Choosing Wisely (CW) recommendation.2
Choosing Wisely recommendations
 Since 2012, Choosing Wisely has asked medical orga-
nizations to identify tests or procedures commonly used in 
their field whose need should be questioned and discussed. 
The fundamental purpose of Choosing Wisely is to reduce 
unnecessary medical tests and treatments. Its mission is 
to help patients choose care that respects four core prin-
ciples: 1) supported by evidence; 2) not duplicative of other 
tests or procedures already received; 3) free from harm; 4) 
truly necessary.3 The recommendations should be based on 
the best available evidence, which entails a broad literature 
review that includes secondary evidence sources such as 
systematic reviews and guidelines, thus avoiding the pos-
sibility of selective choices amongst competing evidence.
 Recommending annual breast cancer screening from 
age 40 onwards does not serve this purpose and does not 
respect the principles cited in the Choosing Wisely mission 
statement. This Choosing Wisely recommendation is based 
on a non-systematic, non-patient-oriented guideline,4 which 
does not give us a full perspective on breast cancer screen-
ing literature. Firstly, scientific evidence is controversial re-
garding screening between 40 and 49 years of age, as ex-
plained further in this article and also mentioned in the sup-
porting literature in the aforementioned guideline. Secondly, 
this procedure can result in harm. Although there is a strong 
body of evidence regarding false positives, overdiagnosis 
and cancer anxiety, it appears to have been overlooked in 
this recommendation.
Experts cannot agree on breast cancer screening.
 Most governmental and scientific organizations recom-
mend breast cancer screening in women as a way to save 
lives and reduce suffering.4–9 The age at which screening 
should start, its frequency and when it should end is far 
more controversial. Table 1 offers a non-systematic over-
view of guidelines about cancer screening. It exemplifies 
how authoritative organizations have reached different rec-
ommendations with the same body of evidence available.
 This level of disagreement is unsurprising when we look 
at the evidence. Consider the decision regarding whether to 
screen women aged 40 - 50. Imagine that you are part of a 
guideline panel, and you are provided with the following evi-
dence about breast cancer screening (estimates calculated 
from data in the appendixes of reference 11):
• In the 40 – 44-year-old group there is moderate qual-
ity evidence that screening leads to 48 fewer breast 
cancer deaths per 100 000 screened women (95% 
CI: -96 to +8 deaths).
• In the 45 – 49-year-old group there is moderate qual-
ity evidence that screening leads to 84 fewer breast 
cancer deaths per 100 000 screened women (95% 
CI: -168 to + 14 deaths).
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• There is moderate quality evidence that in a 
screened population of 100 000 women, 186 women 
are overdiagnosed with cancer (95% CI: 148 to 224 
women), meaning that these women are diagnosed 
with a slow-growing breast cancer that would not 
lead to symptoms within their lifetime and would not 
need any treatment.
•  There is very low-quality evidence that 29 000 in 
100 000 women receive at least one false-positive 
mammogram and that 4000 in 100 000 women 
receive a false-positive biopsy result. Low quality 
evidence also suggests that women who receive a 
false-positive mammogram experience greater dis-
tress, fear and anxiety about breast cancer for up to 
35 months, even though there are no differences in 
clinical anxiety or depression. 
 Your final decision will depend on taking several factors 
into account. Even using this simplified body of evidence, 
you not only need to compare outcomes that are qualita-
tively different, such as saving one life versus the experi-
ence of overdiagnosis, you also need to recognize that the 
evidence is imperfect due to risk of bias and lack of preci-
sion and, finally, you also need to be aware of the difficulty 
of applying such evidence base to your own setting.
 Regarding screening frequency, there are no random-
ized trials that provide comparative evidence of the effect of 
different time intervals on outcomes. Evidence from obser-
vational studies, data extrapolated from clinical trials and 
statistical modelling studies suggest that increased screen-
ing frequency leads to higher breast cancer detection, but 
also leads to higher cumulative false-positive screening 
rates and overdiagnosis. Guideline panels must therefore 
decide on screening frequency based on judgements of the 
optimal balance between the benefit of decreased mortal-
ity and the possible harm of overdiagnosis or false-positive 
results. The evidence suggests that most women attribute 
more value to a small reduction in mortality and less value 
to a larger increase in overdiagnosis or false-positive re-
sults, but individual decisions are very dependent on per-
sonal values. There are also opportunity costs to think of, 
such as displacement of resources. Without direct evidence 
from randomized trials, decisions need to be based on a 
logical argument and modelling studies, which try to predict 
outcomes based on several assumptions. 
 In summary, there is low quality evidence supporting de-
cisions about when to start, how often to screen and when 
to end screening. The overall decision involves balancing 
benefits and harms which are valued differently by relevant 
groups within society. Different authoritative organizations 
propose a wide range of conflicting recommendations, both 
strong and conditional, for the same age cohorts, which 
demonstrates the lack of consensus between experts. We 
therefore consider that the recommendation suggested 
by the College of Radiology to start annual breast cancer 
screening at the age of 40 does not fulfil criteria for a CW 
recommendation.
The key distinction between a strong and a conditional 
recommendation
 A strong recommendation for an intervention (e.g. 
screening) should be issued when the guideline panel is 
confident that the benefits outweigh the harms.10 In other 
words, when most informed patients would want that inter-
vention and only a small proportion would not, and when 




40 - 49 years old
Screening interval Recommendation for women aged 70+
North American organisations
U.S. Preventive Services Task Force 
(2016)3 Shared decision making Every 2 years Up to age 74
American College of Obstetricians and 
Gynecologists (2017)4 Shared decision making
1 to 2 years, after informed 
decision making At least to age 75
American College of Physicians 
(2019)5 Shared decision making Every 2 years Up to age 74
American Cancer Society (2015)6
40 - 44 Shared decision 
making
45 - 49 Screen
1 year 45 - 54
1 to 2 years 55+
If life expectancy > 10 
years
American College of Radiology 
(2017)7 Screen Every year
Individualize to current 
health and life expectancy
Canadian Preventive Task Force on 
Preventive Healthcare (2018)8 Do not screen 2 to 3 years Up to age 74
European organisations
European Commission Initiative on 
Breast Cancer (2019)11
40 - 44 do not screen 
(conditional)
45 - 49 screen (conditional)
45 every 2 - 3 years
50 - 69 every 2 years
70 - 74 every 3 years
Up to age 74
NHS England12 Not included in breast cancer screening programme Every 3 years Up to age 71
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most clinicians agree, then they should offer it to most pa-
tients. Policymakers should adopt that intervention as a 
general policy for most of the population. Conditional rec-
ommendations are issued when the guideline panel agrees 
that the desirable effects of adherence to a recommendation 
probably outweigh the undesirable effects. In other words, 
many but not most patients would choose that procedure, 
and clinicians acknowledge that different options are ap-
propriate for different patients, and therefore a personalized 
decision-making approach, integrating patients’ values and 
preferences, is required. Finally, policymakers should ac-
knowledge that the procedure still requires substantial de-
bate involving all relevant stakeholders. 
The way forward
 The current Choosing Wisely breast cancer screening 
statement does not take into account concerns about the 
balance of benefits and harms in breast cancer screening. 
We suggest that the statement should be subject to further 
debate between relevant stakeholders such as medical spe-
cialties directly involved in breast cancer screening, such 
as General Surgery, Gynaecology, Family Medicine, Public 
Health and Radiology, as well as representatives of women 
and patient groups. This debate should focus on providing 
a recommendation supported by all, that facilitates the dif-
ficult decision of choosing a screening program that is best 
suited to individual preferences and values.
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